Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]
Link to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]
Link to Full Article Cambridge, United Kingdom – 14 January 2021 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with the Congenica Board of Directors and wider senior leadership team, this group […]
Link to Full Article Cambridge, United Kingdom – 12 January 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announced it has launched a local cloud solution that will enable researchers in China to perform more efficient genomic analysis at scale, helping to improve […]
Link to Full Article GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021. Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and […]
Link to Full Article Phase 2b clinical trial of XF-73 completes patient recruitment Results expected in Q1 2021 Brighton, United Kingdom – 5th January 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that its XF-73 […]
Link to Full Article GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021. Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and […]
Link to Full Article Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the […]
Link to Full Article ARESTAT™ formulated product progressing into clinical trial Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, […]
Link to Full Article AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: